Drug reference

lenvatinib

multikinase inhibitor, antiangiogenic · antineoplastic, targeted therapy

multikinase inhibitor, antiangiogenicantineoplastic, targeted therapy

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AmiodaroneSevereDatabaseDDInter
AmisulprideSevereDatabaseDDInter
AnagrelideSevereDatabaseDDInter
Arsenic TrioxideSevereDatabaseDDInter

Mechanism

Multikinase inhibitor; vascular endothelial growth factor receptors are an important target.

Indications

systemic therapy of follicular cell-derived thyroid cancers without regard to driver mutation statussystemic therapy for radioiodine-refractory, progressive thyroid cancersrecurrent or metastatic differentiated thyroid canceradvanced RCC (in combination with everolimus) following one prior antiangiogenic therapyfirst-line treatment of unresectable hepatocellular carcinomaendometrial carcinoma that progressed after systemic treatment (in combination with pembrolizumab)

Pharmacokinetics

Half-life

28 h (elimination)

Metabolism

CYP3A

Side effects

Serious

hypertension
cardiac dysfunction
thromboembolism
impaired wound healing
osteonecrosis of the jaw

Pregnancy & lactation

Pregnancy